Latest News about MRK
Recent news which mentions MRK
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
April 18, 2025
From Benzinga
Where Will Eli Lilly Be in 5 Years?
April 18, 2025
From Motley Fool
Price Over Earnings Overview: Merck & Co
April 15, 2025
From Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
April 15, 2025
From Benzinga
Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic'
April 15, 2025
From Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
April 11, 2025
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
From Benzinga
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
April 09, 2025
From Benzinga
From Motley Fool
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
April 07, 2025
From Benzinga
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
April 04, 2025
From Benzinga
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
April 03, 2025
From Benzinga
2 Beaten-Down Stocks to Buy and Hold for a Decade
April 02, 2025
From Motley Fool
Why Major Pharmaceutical Stocks Tumbled on Tuesday
April 01, 2025
From Motley Fool
From Motley Fool
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
March 28, 2025
From Motley Fool
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
March 25, 2025
From Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
March 25, 2025
From Motley Fool
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
March 25, 2025
From Benzinga
From Benzinga
From Benzinga
2 Beaten-Down Stocks to Buy on the Dip
March 22, 2025
From Motley Fool
From Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
March 17, 2025
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.